Data gathered: January 21
AI Stock Analysis - Crispr Therapeutics (CRSP)
Analysis generated January 10, 2025. Powered by Chat GPT.
Crispr Therapeutics, a leading biotechnology firm, is at the forefront of gene editing technology. The company leverages CRISPR/Cas9 technology to develop transformative gene-based medicines for severe diseases. Founded in 2013 by leading pioneers in CRISPR/Cas9 gene editing, the company has focused on providing revolutionary treatments for genetic disorders and oncology. Crispr Therapeutics is driven by its mission to create breakthroughs in medicine by changing fundamental aspects of genetic makeup. The company’s approach exhibits great potential in sectors where there are currently limited treatment options, which could provide substantial growth opportunities in the long term.
Stock Alerts - Crispr Therapeutics (CRSP)
 |
Crispr Therapeutics | January 15 Price is up by 5% in the last 24h. |
|
Crispr Therapeutics | January 13 Price is down by -6.1% in the last 24h. |
|
Crispr Therapeutics | January 10 Price is down by -5.8% in the last 24h. |
|
Crispr Therapeutics | January 6 Price is up by 6.1% in the last 24h. |
Alternative Data for Crispr Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 67,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 54 | Sign up | Sign up | Sign up |
| Patents | 194 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 38,410 | Sign up | Sign up | Sign up |
| Twitter Followers | 22,338 | Sign up | Sign up | Sign up |
| Twitter Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 43 | Sign up | Sign up | Sign up |
| Business Outlook | 46 | Sign up | Sign up | Sign up |
| Linkedin Employees | 440 | Sign up | Sign up | Sign up |
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
| Price | $41.51 |
| Target Price | Sign up |
| Volume | 1,800,000 |
| Market Cap | $3.46B |
| Year Range | $38.36 - $65.26 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Crispr Therapeutics call volume above normal and directionally bullishJanuary 21 - Thefly.com |
 |
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 5.4% in DecemberJanuary 20 - ETF Daily News |
 |
Cathie Wood's ARK Investment bought 133K shares of Crispr Therapeutics todayJanuary 16 - Thefly.com |
|
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Wealth Enhancement Advisory Services LLCJanuary 16 - ETF Daily News |
 |
CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)January 14 - SeekingAlpha |
|
Nordea Investment Management AB Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)January 11 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 600,000 | 17M | -17M | -86M | -105M | -1.010 |
| Q2 '24 | 520,000 | 19M | -19M | -126M | -146M | -1.490 |
| Q1 '24 | 500,000 | 18M | -17M | -117M | -136M | -1.430 |
| Q4 '23 | 201M | 16M | 185M | 89M | 74M | 1.100 |
| Q3 '23 | 0 | 18M | -18M | -112M | -132M | -1.410 |
Insider Transactions View All
| Kulkarni Samarth filed to sell 181,540 shares at $55.1. December 4 '24 |
| Kulkarni Samarth filed to sell 196,540 shares at $56.3. November 13 '24 |
| Kulkarni Samarth filed to sell 203,419 shares at $55.4. November 13 '24 |
| Kulkarni Samarth filed to sell 226,540 shares at $46.3. October 15 '24 |
| KASINGER JAMES R. filed to sell 62,597 shares at $46.3. October 15 '24 |
Similar companies
Read more about Crispr Therapeutics (CRSP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Crispr Therapeutics?
The Market Cap of Crispr Therapeutics is $3.46B.
What is the current stock price of Crispr Therapeutics?
Currently, the price of one share of Crispr Therapeutics stock is $41.51.
How can I analyze the CRSP stock price chart for investment decisions?
The CRSP stock price chart above provides a comprehensive visual representation of Crispr Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crispr Therapeutics shares. Our platform offers an up-to-date CRSP stock price chart, along with technical data analysis and alternative data insights.
Does CRSP offer dividends to its shareholders?
As of our latest update, Crispr Therapeutics (CRSP) does not offer dividends to its shareholders. Investors interested in Crispr Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Crispr Therapeutics?
Some of the similar stocks of Crispr Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.